Navigation Links
Meta-analysis: Radiotherapy variants improve survival in non-metastatic lung cancer
Date:4/30/2010

A new meta-analysis reported at the second European Lung Cancer Conference shows that patients with both non-small-cell lung cancer and small-cell lung cancer benefit in terms of overall survival when treated with hyperfractionated or accelerated radiotherapy.

Patients treated with hyperfractionated or accelerated radiotherapy regimens are given their treatments more frequently, and over a shorter period of time. The benefit of doing this has been in question as different randomized trials have given contradictory results.

Dr Cecile Le Pechoux and colleagues from Institut Gustave Roussy in Villejuif, France analyzed 10 trials including 2,279 patients with non-metastatic lung cancer. They found that in the eight trials dealing with non-small-cell lung cancer, modified fractionation of the radiotherapy improved overall survival compared to conventional radiotherapy, resulting in an absolute benefit of 3% after 5 years, meaning that 3% more of the patients were alive after 5 years in the modified fractionation groups.

"The clinical benefit we found was small, but comparable to the benefit found in other meta-analyses concerning non-small-cell lung cancer," Dr Le Pechoux said.

Lung cancer remains a major cause of death worldwide with more than 1.1 million deaths per year. Non-small-cell lung cancer (NSCLC) represents more than 80% of all lung tumors and small-cell lung cancer (SCLC) less than 20%. Approximately 35% of patients with NSCLC, and less than a third of SLSC patients, present with locally advanced, non-metastatic disease. The standard treatment for these patients is combined radio-chemotherapy.

In small-cell lung cancer, which is a less common form of the disease, similar results were found, although the difference in survival between the standard and modified radiotherapy regimens was not statistically significant because of lack of power.

These results could encourage further work to determine how best to deliver radiotherapy for lung cancer patients, Dr Le Pechoux said. "Interest in modified fractionation was uncertain before the meta-analysis, but the current results will lead to renewed interested in this research field."

"In the most recent meta-analysis evaluating the best way to combine radiotherapy and chemotherapy in NSCLC, the results showed that concomitant chemo-radiation (5-year survival rate of 15.1%) is superior to sequential chemo-radiation (5-year survival rate of 10.6%) and the best results shown in randomized trials in small-cell lung cancer limited disease show 5-year survival rates of 20-25%. Thus there is need for improvements of both radiotherapy and chemotherapy," Dr Le Pechoux said.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. 4-D software helps adjust for breathing when treating lung cancer with radiotherapy
2. Tool allows precise targeting of radiotherapy for cancer radiation therapy
3. Concord Medical Enters Agreement to Acquire Four Radiotherapy and Diagnostic Imaging Centers in Hebei Province
4. Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients
5. Breakthrough in radiotherapy promises targeted cancer treatment
6. Two-day symposium in Baltimore to tackle the promises and perils of proton radiotherapy
7. New gene variants associated with glucose, insulin levels, some with diabetes risk
8. Identification of genetic variants affecting age at menopause could help improve fertility treatment
9. Common gene variants influence risk factor for sudden cardiac death
10. Common gene variants increase risk of hypertension, may lead to new therapies
11. International study identifies gene variants associated with early heart attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer ... that they have entered into a multiyear collaboration to identify and characterize novel ... additional tools for gene editing across all applications. , Under the terms of ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its ... announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of ... been selected for membership in ARCS Alumni Hall of Fame . ASTER ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/10/2017)... CALIF. (PRWEB) , ... October 10, 2017 , ... San ... part of its corporate rebranding initiative announced today. The bold new look is ... reach, as the company moves into a significant growth period. , It will also ...
Breaking Biology Technology: